Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANGLE plc stock logo
ANPCY
ANGLE
C$1.10
C$1.02
C$0.74
C$2.74
N/AN/A1,170 shs1 shs
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$0.19
+49.5%
$0.17
$0.12
$2.90
N/AN/A8,515 shs1,531 shs
DiaSorin S.p.A. stock logo
DSRLF
DiaSorin
$104.69
$107.88
$100.01
$109.60
$5.73B0.01100 shsN/A
Epigenomics AG stock logo
EPGNY
Epigenomics
$2.39
$2.39
$2.01
$2.39
N/AN/A100 shsN/A
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANGLE plc stock logo
ANPCY
ANGLE
0.00%0.00%+10.98%-40.43%-57.69%
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
+49.46%+50.62%+28.68%-51.79%-7.48%
DiaSorin S.p.A. stock logo
DSRLF
DiaSorin
0.00%0.00%-3.96%+4.42%-3.95%
Epigenomics AG stock logo
EPGNY
Epigenomics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ANGLE plc stock logo
ANPCY
ANGLE
N/AN/AN/AN/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
DiaSorin S.p.A. stock logo
DSRLF
DiaSorin
N/AN/AN/AN/AN/AN/AN/AN/A
Epigenomics AG stock logo
EPGNY
Epigenomics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ANGLE plc stock logo
ANPCY
ANGLE
0.00
N/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
0.00
N/AN/AN/A
DiaSorin S.p.A. stock logo
DSRLF
DiaSorin
2.00
HoldN/AN/A
Epigenomics AG stock logo
EPGNY
Epigenomics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ANGLE plc stock logo
ANPCY
ANGLE
N/AN/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$8.81MN/AN/AN/AN/AN/A
DiaSorin S.p.A. stock logo
DSRLF
DiaSorin
$1.24B4.61$9.27 per share11.29N/A
Epigenomics AG stock logo
EPGNY
Epigenomics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ANGLE plc stock logo
ANPCY
ANGLE
N/A-C$0.48N/AN/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/A0.00N/AN/AN/AN/AN/A
DiaSorin S.p.A. stock logo
DSRLF
DiaSorin
$173.01MN/A0.00N/AN/AN/AN/A7/28/2025 (Estimated)
Epigenomics AG stock logo
EPGNY
Epigenomics
N/A-$3.05N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ANGLE plc stock logo
ANPCY
ANGLE
N/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/AN/AN/A
DiaSorin S.p.A. stock logo
DSRLF
DiaSorin
N/AN/AN/AN/AN/A
Epigenomics AG stock logo
EPGNY
Epigenomics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ANGLE plc stock logo
ANPCY
ANGLE
N/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/A
DiaSorin S.p.A. stock logo
DSRLF
DiaSorin
N/A
3.12
1.89
Epigenomics AG stock logo
EPGNY
Epigenomics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ANGLE plc stock logo
ANPCY
ANGLE
N/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/A
DiaSorin S.p.A. stock logo
DSRLF
DiaSorin
N/A
Epigenomics AG stock logo
EPGNY
Epigenomics
N/A

Insider Ownership

CompanyInsider Ownership
ANGLE plc stock logo
ANPCY
ANGLE
N/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/A
DiaSorin S.p.A. stock logo
DSRLF
DiaSorin
N/A
Epigenomics AG stock logo
EPGNY
Epigenomics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ANGLE plc stock logo
ANPCY
ANGLE
173N/AN/ANot Optionable
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
10N/AN/ANot Optionable
DiaSorin S.p.A. stock logo
DSRLF
DiaSorin
3,18654.71 millionN/ANot Optionable
Epigenomics AG stock logo
EPGNY
Epigenomics
32N/AN/ANot Optionable

Recent News About These Companies

Seminar Series
SBC Job OpportunitiesJoin our team!
Colon Ischemia: Don't Miss This

Media Sentiment Over Time

ANGLE stock logo

ANGLE OTCMKTS:ANPCY

C$1.10 0.00 (0.00%)
As of 05/27/2025

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

bioAffinity Technologies stock logo

bioAffinity Technologies NASDAQ:BIAFW

$0.15 +0.02 (+13.85%)
As of 05/28/2025 03:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

DiaSorin stock logo

DiaSorin OTCMKTS:DSRLF

$104.69 0.00 (0.00%)
As of 05/27/2025

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

Epigenomics stock logo

Epigenomics OTCMKTS:EPGNY

$2.39 0.00 (0.00%)
As of 04/6/2023

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.